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Abstract
A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney 
Diseases to address the research gaps and opportunities in pancreatic endoscopic ultrasound 
(EUS). The event occurred on July 26, 2017 in 4 sessions: (1) benign pancreatic diseases, (2) high-
risk pancreatic diseases, (3) diagnostic and therapeutics, and (4) new technologies. The current 
state of knowledge was reviewed, with identification of numerous gaps in knowledge and research 
needs. Common themes included the need for large multicenter consortia of various pancreatic 
diseases to facilitate meaningful research of these entities; to standardize EUS features of different 
pancreatic disorders, the technique of sampling pancreatic lesions, and the performance of various 
therapeutic EUS procedures; and to identify high-risk disease early at the cellular level before 
macroscopic disease develops. The need for specialized tools and accessories to enable the safe 
and effective performance of therapeutic EUS procedures also was discussed.
EUS became commercially available in the 1980s with the seminal publications by 
DiMagno et al1 and Hisanaga et al2,3 demonstrating the feasibility and safety of mounting an 
US transducer on the tip of a rigid endoscope and using this to examine the GI wall and 
extraluminal space. Since then, EUS with the addition of FNA has established itself as the 
premier diagnostic tool for staging many GI luminal cancers, evaluating intramural lesions, 
and assessing the immediate extraluminal space. It has assumed particular importance in the 
diagnosis of pancreatic cancers as well as other pancreatic diseases and more recently has 
evolved into a key vehicle for a variety of therapeutic procedures. The National Institute of 
Diabetes and Digestive and Kidney Diseases workshop, “Endoscopic ultrasound and related 
technologies for the diagnosis and treatment of pancreatic disease: research gaps and 
opportunities,” sought to review the latest knowledge and set priorities for future 
investigation.
EUS remains the diagnostic test of choice for diagnosing pancreatic masses. Although some 
advocate for surgical resection without biopsy, sampling these masses to determine the exact 
diagnosis remains important because a significant minority of these patients do not have 
pancreatic adenocarcinoma and those who do are increasingly requiring precision therapy. 
Nearly 15% of pancreatic masses are metastatic lesions, with another 1% to 2% being 
lymphomas and 5% to 11% autoimmune pancreatitis. Neoadjuvant therapy may improve 
outcomes, with 41% of borderline resectable tumors converted to resectable lesions after 
therapy.4 Concerns over the potential spread of malignant cells by performing EUS-guided 
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FNA (EUS-FNA) of pancreatic masses were assuaged by a study demonstrating that EUS-
FNA was not associated with decreased survival.5 The ideal technique to ensure the highest 
diagnostic yield remains unclear and will be discussed in greater detail below. Recent 
innovations in core needles may enable acquisition of increased amounts of tissue required 
for molecular assays compared with conventional FNA needles.
Performance of EUS in pancreatic cysts remains controversial, with several guidelines 
offering, at times, discrepant recommendations for indications of EUS.6–8 This stems from 
the inability of currently available cyst fluid analyses to diagnose and accurately predict the 
malignant potential of these cysts. Therefore, translational research has flourished, with 
investigations involving proteomics, metabolomics, and DNA and RNA analyses all 
demonstrating a variety of promising markers including DNA methylation markers to 
discriminate cysts with malignancy or high-grade dysplasia from those with low-grade or no 
dysplasia.9 Large prospective validation studies are required to establish which markers or 
combination of markers would be most efficacious.
Another problematic area involves the diagnosis of chronic pancreatitis, with the American 
Pancreatic Association practice guidelines concluding that EUS features of chronic 
pancreatitis may represent not only chronic pancreatitis but also pancreatopathy, an 
asymptomatic presence of fibrosis without inflammation caused by a variety of factors 
including aging and exposure to alcohol or smoking.10 Furthermore, interobserver 
agreement among experienced endosonographers for various chronic pancreatitis features 
remains inadequate despite the more recent Rosemont criteria.11,12 Autoimmune pancreatitis 
is another (AP) condition in which EUS may be helpful but remains difficult to diagnose and 
differentiate from pancreatic ductal adenocarcinoma (PDAC).
EUS-guided therapeutics began with celiac plexus neurolysis, which has proven effective 
and durable in treating pancreatic cancer pain. Initial reports of the surgical technique in 
which patients were randomized in a double-blind study to neurolysis with 50% alcohol 
compared with saline solution interestingly demonstrated not only improved pain control 
through 6-month follow-up but also increased survival in these patients, which remains 
poorly understood.13 A randomized trial comparing conventional pain management to EUS-
guided celiac plexus neurolysis also reported improved pain control, although there was no 
difference in quality of life.14
Another well-established therapeutic intervention with EUS is drainage of pseudocysts and 
walled-off pancreatic necrosis. Standard of care in initial management of these conditions 
has dramatically evolved from surgical drainage and debridement to endoscopic and 
percutaneous approaches. However, controversy still exists about when, in whom, and how 
to perform endoscopic necrosectomy. Recent interest has centered around the use of lumen 
apposing metal stents (LAMSs) to facilitate these procedures, with some studies suggesting 
increased rates of bleeding associated with LAMS placement.15 Multiple retrospective 
studies have published discrepant findings with respect to success of procedures and need 
for repeat procedures when LAMSs are compared with plastic stents.16–18 Large prospective 
randomized trials are needed to understand the best setting for each type of stent.
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The National Institute of Diabetes and Digestive and Kidney Diseases workshop occurred at 
an important time when EUS of the pancreas has established itself as the optimal diagnostic 
and therapeutic technique for a variety of pancreatic diseases but requires further 
development in several critical areas including pancreatic cystic lesions, chronic pancreatitis, 
fatty pancreas, early detection of high-risk pancreatic lesions, and various therapeutics. The 
lectures and sessions provided expert analyses of the issues facing EUS of the pancreas in 
the 21st century as well as a framework for next steps needed to advance the field forward.
EUS PERFORMANCE AND INTERPRETATION IN BENIGN PANCREATIC 
DISEASES
Overview of the Problem
EUS is a technically challenging procedure that requires advanced training beyond those 
required for performing upper and lower endoscopy. These aspects contribute to operator 
variability that impacts competency and diagnostic interpretation of several benign 
pancreatic disorders including chronic pancreatitis, autoimmune pancreatitis, and fatty 
pancreas.
Assessing Competency in Pancreatic EUS
EUS is taught predominantly by apprenticeship, with competence primarily measured by 
procedure volume. Although the threshold volume varies among societies, the American 
Society for Gastrointestinal Endoscopy has defined this as 225 cases before competency can 
be assessed.19 This target is based on expert opinion and does not account for the different 
rates at which trainees learn. Data from a multicenter study that used a validated skills 
assessment tool—The EUS and ERCP Skills Assessment Tool, with cumulative-sum 
analysis, demonstrated substantial variability among trainees in achieving competence in 
EUS, and suggested that competence is not assured after completing 225 cases.20
These results highlight the limitation of volume-based competency metrics and indicate that 
EUS training needs to evolve toward a curriculum that focuses on competence-based 
medical education—a reform promoted by the Accreditation Council for Graduate Medical 
Education-Next Accreditation System. These reforms would include establishing minimum 
standards for advanced endoscopy training programs that incorporate trainee assessment 
through competency-based milestones of both technical and cognitive skills. It would also 
include education on systematically measuring and monitoring EUS performance against 
defined metrics of a high-quality EUS examination.21 Limited exposure to therapeutic EUS 
techniques during training necessitates the development of specific training strategies to 
address this issue as well.
EUS in Differentiating Normal Pancreas, Minimal Change Chronic Pancreatitis, and Other 
Pancreatopathies
In clinical practice, the diagnosis of chronic pancreatitis is typically made when obvious 
parenchymal and/or ductal changes in the pancreas are apparent on cross-sectional studies, 
that is, CT and/or magnetic resonance imaging (MRI)/MRCP). These changes, however, 
may occur at variable times (sometimes years) after the onset of clinical symptoms. Minimal 
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change chronic pancreatitis is a term used to describe patients who have symptoms 
suggestive of chronic pancreatitis, most commonly chronic abdominal pain, but normal or 
equivocal cross-sectional imaging test results. In these patients, diagnosing chronic 
pancreatitis remains challenging and may be aided by identifying parenchymal and/or ductal 
changes on EUS.
The criteria used to diagnose chronic pancreatitis on EUS includes a non-weighted and 
weighted score that incorporates stricter definitions for minor and major features, which 
appear to reflect pancreatic fibrosis.22 However, establishing a diagnosis of chronic 
pancreatitis solely by using EUS has limitations. EUS may play a role as part of a more 
comprehensive diagnostic model incorporating various risk factors for chronic 
pancreatitis.23 There remains high interobserver variability for individual findings and 
overall scoring among experienced endosonographers.12 Several conditions, including 
increasing age, smoking, alcohol consumption, and diabetes may cause parenchymal and/or 
ductal changes without symptoms (defined by the term pancreatopathy),24,25 making it 
difficult to determine if changes observed on EUS result from chronic pancreatitis or merely 
from these confounding factors. Studies have compared EUS features with MRCP (with or 
without secretin), secretin-stimulated pancreatic function testing, and histology.26 Although 
some comparisons are promising, the lack of a criterion standard and the role of 
confounding factors have not been appropriately addressed.
EUS in Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Cancer
Autoimmune pancreatitis (AIP) is a relatively rare form of chronic pancreatitis that afflicts 
not only the pancreas but also other organs including the bile duct. Both AIP and chronic 
pancreatitis may present with focal mass-forming disease that can mimic PDAC, and 
accurate distinction of these 3 disease processes is important for providing disease-
appropriate care and for enhancing patient outcomes.27 Patients with unrecognized AIP or 
chronic pancreatitis continue to undergo pancreatic resection for presumed malignancy. In 
addition, delayed or failed diagnosis of AIP risks allowing disease progression to chronic 
pancreatitis changes. Although many studies have evaluated the accuracy of EUS for 
diagnosing PDAC and for assessing chronic pancreatitis ductal and parenchymal features, 
there is a paucity of data evaluating EUS features of AIP as well as the ability of EUS to 
distinguish among these disease processes.
Well-designed studies are needed to evaluate the capability of EUS for diagnosing and 
distinguishing AIP, chronic pancreatitis, and PDAC based on conventional and potentially 
new EUS imaging criteria and to evaluate EUS-associated technologies such as 
elastography, contrast-enhanced imaging, and computer-aided techniques.28 Understanding 
the potential utility of EUS to distinguish type 1 and 2 AIP and to predict therapeutic 
response is also warranted. Studies that clarify the relative value of EUS-guided cytologic 
versus histologic diagnosis by using an appropriate pathology criterion standard are needed.
EUS and Fatty Pancreas
Existence of fat in the pancreas has been known since the 1930s, although the true 
prevalence remains unknown. Fatty pancreas is a radiologic term that describes the presence 
Lee et al. Page 5
Pancreas. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of excess intrapancreatic fat (IPF). Different terms have been used to describe fatty pancreas 
including pancreatic steatosis, non-alcoholic fatty pancreas disease, pancreatic lipomatosis, 
lipoatrophy of the pancreas, pancreatic fatty infiltration, and pancreatic fatty replacement. 
Although fatty pancreas is common in certain genetic disorders (eg, Shwachman-Diamond 
syndrome, cystic fibrosis), in the vast majority of patients, it accompanies obesity, advanced 
age, diabetes, and fatty liver.29–31 The pathophysiologic mechanisms that lead to excess 
intrapancreatic fat deposition and the clinical and metabolic implications are only beginning 
to be understood.
The diagnostic criteria for fatty pancreas are subjective and variable. A wide range of 
techniques have been described for imaging intrapancreatic fat, including transabdominal 
US, CT, MRI, and EUS. On CT, fatty pancreas appears hypodense compared with the 
spleen. On EUS, a grading system adapted from radiology incorporating the echotexture of 
the pancreas relative to the spleen as well as the ability to visualize the main pancreatic duct 
and “salt and pepper” dots in the parenchyma has been suggested to assess fatty pancreas.32 
MRI is the test of choice for identifying intrapancreatic fat. However, there are little data 
correlating findings of intrapancreatic fat on EUS or MRI with histology. In addition, the 
effect of excess intrapancreatic fat on pancreatic exocrine or endocrine function and fibrosis 
remains unclear. Intrapancreatic fat may have a role in causing or aggravating metabolic, 
inflammatory, and neoplastic disease processes. Fatty pancreas has been associated with 
increased severity of acute pancreatitis in the setting of obesity,33 likely because of 
proinflammatory cytokine release from injured fat.34 Some evidence suggests that the 
proinflammatory milieu induced by obesity contributes to pancreatic oncogenesis through 
the activation of K-ras signaling pathways.35 Other important implications of fatty pancreas 
appear to be its tendency to create background noise that could obscure small solid lesions 
that would have implications for early detection of pancreatic cancer. Future studies should 
focus on how to distinguish solid lesions within a fatty pancreas by using EUS.
Research Gaps and Opportunities
Research should focus on interventions to ensure EUS competence and systematically 
reduce operator variability in EUS performance. The role of EUS as a diagnostic or 
prognostic tool for chronic pancreatitis, and whether automation that uses new technology 
can improve its ability needs to be clarified. Further studies correlating EUS observations 
with appropriate histologic standards should be conducted as well as the role of tissue 
acquisition in improving EUS clinical utility. Finally, the epidemiology of fatty pancreas, 
whether and how fatty pancreas may increase the risk of pancreatic conditions need further 
study.
Specific priorities include: (1) validation of novel competency-based metrics for EUS 
training; (2) defining the diagnostic and prognostic ability of EUS in chronic pancreatitis by 
using an appropriate criterion standard such as histology or longitudinal follow-up — such 
studies should evaluate the incremental value of integrating clinical and laboratory data into 
EUS performance; (3) establishing a histologic definition for chronic pancreatitis on surgical 
specimens as well as core biopsy specimens obtained during EUS; (4) evaluating the clinical 
utility of novel EUS-associated imaging modalities including elastography, digital image 
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analysis, contrast-enhanced imaging, and computer-aided techniques in differentiating 
PDAC, chronic pancreatitis, and AIP, and reducing interobserver variability; (5) defining 
EUS criteria for diagnosis of AIP; (6) defining the prevalence of fatty pancreas in the 
general population and in patients with metabolic syndrome and determining whether the 
presence of fatty pancreas predicts the presence or risk of cardiovascular disease; (7) 
establishing the role of intrapancreatic fat in causing inflammation and fibrosis and 
associated mechanisms; and (8) determining whether fatty pancreas increases the risk and 
severity of pancreatic diseases, including acute pancreatitis and pancreatic cancer.
EUS IN HIGH-RISK PATIENTS
Overview of the Problem
Incidental pancreatic cystic lesions are detected ever more frequently because of increased 
use of cross-sectional abdominal imaging. The majority of these cysts are mucinous and thus 
premalignant. Societal guidelines regarding evaluation of pancreatic cysts are controversial 
and based on little evidence. Formal guidelines for screening and surveying high-risk 
individuals with familial pancreatic cancer are lacking.
Cystic Lesions: The Role of EUS, With or Without Other Imaging Technologies For 
Differentiating Benign and Malignant Cysts
Once a cyst has been discovered, the patient should undergo MRI with MRCP to better 
define the cyst and attempt to determine whether it is mucinous or non-mucinous. Mucinous 
cysts (intraductal papillary mucinous neoplasm [IPMN] and mucinous cystic neoplasms) 
may warrant further evaluation depending on size and surgical candidacy. The accuracy of 
MRI for detecting mucinous cysts is 71% to 91%, and for malignant cysts it is 73% to 
91%.36,37 EUS imaging is approximately 50% accurate for differentiating mucinous from 
non-mucinous cysts.38 It may be superior to MRI for detecting small pancreatic masses and 
mural nodules, although interobserver agreement remains an issue with only solid 
component achieving moderately good agreement. Contrast-enhanced EUS may improve the 
ability to diagnose nodules as well as differentiate malignant and benign nodules. However, 
EUS imaging alone remains inadequate for cyst diagnosis. This is confirmed by a study 
demonstrating the superior diagnostic accuracy of the Fukuoka guidelines, which 
incorporate EUS-FNA cytology results for diagnosing malignant cysts compared with the 
Sendai guidelines that rely only on imaging features.39
Cystic Lesions: Cyst Fluid Analysis in the Differentiation of Benign and Malignant Cysts
EUS-FNA of pancreatic cysts enables cyst fluid analysis for diagnostic and prognostic 
purposes. Cyst fluid cytology is very specific for the diagnosis of a malignant cyst, but it 
suffers from poor sensitivity because of paucicellular samples. Carcinoembryonic antigen 
(CEA) measurement in cyst fluid is helpful for the diagnosis of a mucinous cyst, with a 
cutoff value of 192 ng/mL being 80% accurate,38 but the CEA level is not predictive of 
malignancy. Despite inadequate cellularity in most cyst aspirates, DNA and RNA shed into 
the fluid can be analyzed for mutations. Next-generation sequencing is currently being used, 
given its increased sensitivity to detect smaller amounts of DNA and its ability to assay 
multiple genes simultaneously. From a diagnostic standpoint, KRAS is very specific for 
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mucinous cysts (mucinous cystic neoplasms or IPMN), whereas GNAS is specific for IPMN. 
Mutations in TP53, PIK3CA, and PTEN have been associated with advanced neoplasia 
(high-grade dysplasia or invasive cancer) in mucinous cysts, with a sensitivity of 91% and 
specificity of 97%.40,41
Other biomarkers showing promise for diagnosing advanced neoplasia include telomerase, 
microRNA, mucin profiling, and monoclonal antibody (mAb Das-1).
New EUS-guided Technologies for Diagnosis of Cystic Lesions
Needle-based confocal endomicroscopy enables realtime optical biopsies and provides in 
vivo histopathologic assessment during EUS-FNA via a 19-gauge needle.42 Serous 
cystadenomas have been the best studied thus far, demonstrating a typical superficial 
vascular network, whereas IPMNs exhibit papillary projections with an epithelial border and 
vascular core.43 However, the role of confocal endomicroscopy for the diagnosis of 
pancreatic cysts has not been well established. Recently, a microforceps has been developed 
for tissue acquisition from pancreatic cystic lesions. During EUS-FNA, the microforceps is 
introduced through the 19-gauge needle, and pinch biopsies are obtained from the cyst wall, 
septations and nodules, or adjacent masses. In a preliminary study, the tissue acquisition 
yield was 90%, and microforceps histology was superior to EUS-FNA cytology, especially 
for providing a specific pancreatic cyst diagnosis.44 This technology is expected to grow in 
the future, in which real histology could replace cytology, CEA level measurement, and 
diagnostic biomarkers.
The Role of EUS in Screening for Familial Pancreatic Cancer
The goal of pancreatic cancer screening is to detect early cancer and its precursor lesions in 
individuals with inherited genetic susceptibility leading to an increased risk for developing 
pancreatic cancer. These high-risk individuals are defined as either having a family history 
of pancreatic cancer, which includes having at least 2 affected first-degree relatives, or a 
pancreatic cancer-associated genetic syndrome such as Peutz-Jeghers or Lynch syndrome. 
MRI and EUS are suggested as preferred imaging modalities in the hope of detecting 
asymptomatic cancer or high-grade precursor neoplasms (pancreatic intraepithelial 
neoplasms [PanIN-3] or high-grade branch duct IPMNs). Prospective screening in this high-
risk population by using MRI and EUS detects pancreatic lesions in 6% to 42% of 
patients,45,46 with an 8.2% yield for detecting high-grade lesions or incidental cancer.47 
Many questions still remain regarding the optimal method and interval for screening and 
surveillance as well as indications for surgical resection.
Research Gaps and Opportunities
Future research efforts should focus on enhanced cyst imaging, cyst fluid biomarkers, and 
EUS-guided technology to allow differentiation of benign and malignant pancreatic cystic 
lesions and detection of precursor lesions in high-risk individuals. Critical areas of research 
include the following: (1) new radiologic and EUS imaging technology to improve 
differentiation of benign and malignant pancreatic cysts, (2) long-term natural history 
studies of pancreatic cystic lesions, (3) a pancreatic cyst consortium that includes a larger 
surgically confirmed cohort and a longer observation period to perform cyst fluid and tissue 
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biomarker studies and validation studies, (4) determination of the diagnostic yield of 
microforcep biopsies compared with confocal endomicroscopy and standard FNA and/or 
cyst fluid studies for the diagnosis of pancreatic cysts, (5) development of new tissue 
acquisition devices for pancreatic cysts, (6) development and validation of selection criteria 
for surgical resection in high-risk individuals, and (7) definition of the optimal method and 
interval for screening and surveillance in high-risk individuals.
EUS-GUIDED DIAGNOSTICS AND THERAPEUTICS
Overview of the Problem
Although EUS is the preferred method of obtaining tissue for diagnosis of pancreatic 
diseases, and it has become an integral part of patient management as neoadjuvant therapies 
for locally advanced PDACs have evolved, the best technique to optimize diagnostic yield 
remains unclear. Beyond diagnostics, EUS has entered therapeutics in which key issues 
remain regarding lack of appropriate equipment and accessories needed to perform these 
procedures as well as the need to standardize and improve our current techniques for 
endoscopic necrosectomy, EUS-guided pancreatic duct access, and EUS-guided ablative 
therapies.
EUS-guided Tissue Acquisition: Endoscopic and Pathology Considerations
Typically, diagnosis of PDAC has been obtained by using EUS-FNA cytology, which is 
highly accurate, although the advent of newer-generation needles for EUS-guided fine-
needle biopsy has enabled relatively easy and safe core biopsy of the pancreas. At least 13 
different equipment and operator variables may impact the diagnostic yield of EUS-guided 
tissue acquisition: needle size, needle type, specimen handling and processing, presence of 
rapid on-site evaluation, number of passes, number of to and fro movements, fanning, 
central versus peripheral sampling, speed of needle throw, amount and type of suction 
applied, wet versus dry needle, and operator experience. The optimal combination of these 
factors has not been identified. Overall, data do not currently support improved diagnostic 
yield with 25-gauge versus 22-gauge FNA needles, and advantages of the older reverse side-
bevel core biopsy needles compared with standard FNA needles remains unclear, other than 
a likely decreased number of passes needed for diagnosis; suction does appear to improve 
diagnostic accuracy.48–50 Rapid on-site evaluation of EUS-FNA specimens enhances 
diagnostic yield by determining when an adequate tissue sample has been obtained. 
However, rapid on-site evaluation remains expensive, time consuming, unavailable in large 
parts of the world, and is comparable to performing 7 FNA passes into solid pancreatic 
masses.51 Other methods of determining adequacy such as macroscopic on-site evaluation 
require study.
Core biopsy specimens may be required for diagnosis of autoimmune pancreatitis, 
pancreatic lymphoma, and unusual neoplasms such as acinar cell carcinoma. Molecular 
tissue analysis currently guides individualized therapy of many forms of cancer, and it will 
become increasingly relevant to management of PDAC in the near future.52 It is currently 
unclear which tissue acquisition method will most reliably yield adequate tumor DNA 
suitable for molecular analysis.
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EUS-guided Drainage of Pseudocysts and Walled-off Necrosis
Drainage of symptomatic pancreatic pseudocysts and walled-off necrosis (WON) is now 
typically performed under EUS guidance, which affords increased technical success rates 
with fewer complications than traditional endoscopic transmural drainage techniques.53 
Endoscopic treatment of WON results in better patient outcomes compared with surgery as 
well as an initial percutaneous catheter drainage approach, and it has rapidly become the 
preferred initial treatment.54,55 Although pseudocysts typically respond well to current 
management techniques, treatment of WON may require multiple endoscopic interventions 
and a prolonged treatment course with suboptimal complication rates (morbidity reported as 
high as 26% and mortality up to 7.5%).56,57 This likely reflects considerable variability in 
performance of the procedure. Multiple patient and technical factors may affect outcomes of 
endoscopic WON treatment, including age, size, and morphology of the collection, creation 
of 1 versus multiple drainage sites, choice of stents, choice of lavage solution, use of acid 
suppressive therapies, and degree of necrosectomy performed. A standardized approach to 
performing endoscopic necrosectomy recently demonstrated high success rates, with 98.3% 
of patients requiring only 1 treatment session and 3.3% morbidity with no mortality.57 The 
use of LAMSs for drainage of WON has improved the ease and technical success of 
endoscopic drainage, however, retrospective studies have suggested discrepant results when 
comparing LAMSs to plastic stents.15–18 LAMSs have introduced new concerns, including 
formation of stent-related pseudoaneurysms and segregation of remote areas of WON after 
rapid collapse of the central cavity drained by a LAMS. In order to address the relatively 
high adverse event rate and mortality risk associated with endoscopic necrosectomy, each 
component of the procedure should be analyzed to optimize efficiency and safety. Methods 
regarding access, debridement, lavage, drainage, pancreatic stenting, and nasocystic drainage 
must be rigorously evaluated. Other aspects of care such as timing of the initial procedure, 
medication use, and follow-up strategy also must be evaluated with an attempt at 
standardization.
EUS-guided Pancreatic Duct Access
EUS-guided pancreatic duct access is performed to facilitate stenting of obstructed 
pancreatic ducts not accessible by ERCP. The pancreatic duct is punctured with a 19-gauge 
or 22-gauge needle from the stomach or duodenum under EUS guidance. Several variations 
in this procedure have been described, including passage of a guidewire via the EUS needle 
across the ductal obstruction, with subsequent ERCP performed over the guidewire 
(rendezvous procedure), and EUS-guided transmural antegrade placement of stents into the 
pancreatic duct.58 The technique can successfully facilitate endoscopic treatment of 
pancreatic duct obstruction in about 69% to 90% of patients who might otherwise require 
surgical pancreatic resection. However, significant adverse events are seen in 14% to 60% of 
patients. Techniques and accessories require further development and refinement to reduce 
adverse event rates and improve success. At present, these procedures should be performed 
only by highly experienced interventional endosonographers at tertiary-care centers.
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EUS-guided Ablation of Cysts and Tumors
Endoscopic ablation of solid and cystic pancreatic neoplasms has been investigated for over 
15 years, but with some exceptions, it has yet to become a standard of care. Modalities that 
ablate any tissue (including ethanol and radiofrequency ablation) and those that selectively 
target neoplastic cells (such as paclitaxel injection and photodynamic therapy) have been 
studied. Multiple phase 1 studies as well as 1 phase 3 trial of EUS-guided fine-needle 
injection therapies of PDAC have demonstrated the safety of these techniques but have failed 
to show a survival advantage.59 Case series suggest that EUS-guided ethanol injection of 
functional pancreatic neuroendocrine tumors effectively treats symptoms caused by these 
tumors.60
Ablation of cystic neoplasms by EUS-fine-needle injection has shown promise, with 
sequential ethanol and paclitaxel injection demonstrating cyst resolution in two-thirds of 
treated cysts compared with only about one-third resolution after ethanol ablation alone.61 
However, studies have relied on surrogate endpoints, mainly change in cyst volume, rather 
than assessing cancer prevention, and the risk-benefit ratio of these interventions is unclear, 
with reported pancreatitis rates up to 10%.
Research Gaps and Opportunities
Research gaps and opportunities include: (1) create a multicenter EUS-FNA/fine-needle 
biopsy registry to determine optimal methods of EUS-guided pancreatic tissue sampling and 
the impact of these methods on patient outcomes; (2) assess methods of EUS-guided 
sampling for optimal DNA recovery and molecular characterization of pancreatic cancer 
tissue; (3) develop ex vivo models that accurately predict clinical performance of novel EUS 
tissue acquisition devices; (4) develop methods that improve the efficiency, safety, and cost 
in EUS-guided tissue acquisition (such as macroscopic on-site evaluation); (5) develop and 
complete prospective multicenter randomized trials of endoscopic treatment of WON, 
evaluating various aspects of technique (for example, LAMSs vs plastic stents) as well as 
timing of procedure and follow-up; (6) determine best approaches to evaluation and 
management of disconnected pancreatic duct syndrome in patients with pancreatic necrosis; 
(7) develop novel endoscopic devices and techniques for endoscopic drainage and 
debridement of WON, EUS-guided pancreatic duct access and stent placement, and ablation 
of pancreatic cystic and solid neoplasms; (8) assess the impact of local ablative therapies on 
the biology, stage, and treatment responsiveness of PDAC; (9) develop and validate 
surrogate endpoints for prevention of malignancy in pancreatic cystic neoplasms, possibly 
including biomarkers of advanced neoplasia; and (10) assess promising EUS-guided ablative 
methods in prospective, multicenter, adequately powered studies evaluating clinically 
important endpoints.
EUS AND NEW TECHNOLOGIES
Overview of the Problem
The interpretation of EUS images requires expertise, and there is a high rate of variance 
between endosonographers. To overcome these limitations, several image-enhancement 
techniques, such as contrast-enhanced EUS (CE-EUS), elastography, and digital image 
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analysis have been developed recently. More experimental techniques to improve EUS 
imaging and diagnosis of malignancy, including molecular imaging by using microbubbles 
and photoacoustic imaging, hold promise but require further refinement and study in 
humans, whereas the detection of portal venous circulating tumor cells via EUS-FNA may 
allow more accurate staging and management of patients with PDAC.
Can CE-EUS, Elastography, and Digital Imaging Analysis Differentiate Solid Lesions of the 
Pancreas?
CE-EUS uses the unique characteristics of the interaction of gas-filled microbubbles injected 
intravascularly with US energy to image vascularized structures. There are several types of 
microbubble-based US contrast agents (UCAs) with different features, which remain 
unavailable in the United States. The first-generation UCAs were used to perform CE-EUS, 
whereas second-generation UCAs are used with dedicated contrast harmonic algorithms in 
EUS. CE-EUS is the generic term that encompasses all contrast-enhanced techniques 
involved with EUS, whereas contrast harmonic EUS and contrast-enhanced harmonic EUS 
refer to low mechanical index techniques used in CE-EUS. A typical heterogeneous hypo-
enhanced sonographic pattern strongly suggests malignancy, although chronic pancreatitis 
with severe fibrosis produces a similar pattern. Hyperenhancement or iso-enhancement has 
strong negative predictive value for pancreatic cancer.62 Reviews of the utility of UCAs for 
the diagnosis of PDAC reported promising results.63,64 The addition of CE-EUS to EUS 
tissue acquisition may improve the diagnostic accuracy of pancreatic masses and help target 
areas for biopsy. Recent developments include tumor-specific UCAs with antibodies to 
specific entities such as CA 19-9 and nano-bubbles, which unlike microbubbles, can leave 
the vascular space and penetrate tumor tissue. Both of these advancements may increase 
tumor sensitivity and are areas of active investigation.
EUS elastography is an imaging technique that displays in color the differences in tissue 
hardness, thus estimating elasticity distribution in normal and target areas. For quantitative 
analysis, the strain ratio, which numerically expresses elasticity in the target area relative to 
a reference soft tissue area, is used. However, a meta-analysis showed low pooled specificity 
of 67% for the diagnosis of solid pancreatic masses, suggesting difficulties in the setting of 
severe fibrosis.64 Therefore, computer-assisted technology will likely be needed to improve 
accuracy.
Digital image analysis has been developed to improve diagnostic accuracy and shorten the 
interpretation process. This is a method to quantify and analyze image information by 
mathematic or statistical methods by using artificial intelligence with learning algorithms 
such as artificial neural networks or support vector machines. Digital image analysis can 
increase the diagnostic rate of not only B-mode but also CE-EUS or elastography.65,66 
Further development of digital image analysis requires randomized multicenter trials, a data 
registry to enable data mining, and the development of user-friendly programs that can be 
incorporated into clinical care.
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US-guided Microbubble Techniques for Molecular Imaging and Drug Delivery
Molecular imaging by using US builds on the technique of CE-EUS by using ligands 
attached to the surface of the microbubble that have affinity for specific endothelial 
molecular targets.67,68 By attaching ligands such as antibodies to the surface of gas-filled 
microbubbles, foci of abnormal endothelium can be imaged by using US. In a genetic mouse 
model of pancreatic cancer, Pysz et al69 demonstrated the ability of microbubbles that target 
vascular endothelial growth factor type 2 receptors to enhance the signal of small foci of 
pancreatic cancer by 27-fold. This study demonstrated the feasibility of performing 
molecular imaging by using US. Proteomic analysis identified thymocyte differentiation 
antigen 1, a marker of neovasculature in human PDAC. UCAs labeled with anti-human 
thymocyte differentiation antigen 1 antibody demonstrated an increased US signal in mice 
with pancreatic cancer compared with mice with chronic pancreatitis and wild-type 
controls.70 Although this has yet to be tested in humans for detection of PDAC, it has been 
demonstrated to be safe and feasible in patients with both breast and ovarian lesions.71
Microbubbles also can be used to enhance drug delivery in a targeted fashion.72 Various 
mechanisms have been investigated for US-enhanced drug delivery including sonoporation, 
intravascular cavitation, extravascular cavitation, and the use of temperature-sensitive 
liposomes. Microbubbles in an US field can disrupt cell membranes and endothelial gap 
junctions, and microbubble cavitation can release drugs that are loaded into liposomes 
coadministered intravascularly. US that is delivered at sufficient peak-negative pressures can 
cause tissue destruction without the need for administered microbubbles. This has the 
benefit of being able to disrupt the stromal matrix in pancreatic tumors, without disrupting 
the vasculature, enhancing the ability of drug to penetrate into tumors.73 Lastly, US can be 
used to create local hyperthermia, allowing for drug-loaded temperature-sensitive liposomes 
or other photosensitizers to release their payload within a targeted region.74 Clinical 
translation of these methods awaits the development of a high-intensity focused US 
endoscope.75
Photoacoustic Imaging of the Pancreas—Lessons Learned From Other Malignancies
Photoacoustic imaging of targeted biomarkers is a promising technique for noninvasive 
molecular imaging to accurately diagnose and stage pancreatic tumors. Photoacoustic 
imaging or optoacoustic technology is a state-of-the-art medical imaging modality that 
provides quantitative optical contrast by using energy conversion from absorbed short-pulse 
light energy to acoustic waves in the tissue.76 With the aid of photoacoustic imaging optical 
contrast agents that bind to diagnostic and prognostic biomarkers of pancreatic cancer, 
photoacoustic imaging holds great potential as a noninvasive imaging tool that will enable 
visualization of clinically important pathologic changes at early stages of tumor 
development.77 Combined with conventional EUS by adding a laser light delivery system, 
photoacoustic imaging can provide anatomic and functional information for more reliably 
differentiating and staging a tumor.
The current endoscopic photoacoustic device used in animal studies needs to be adapted for 
clinical applications.78 Although technical concerns with endoscopic photoacoustic imaging 
due to light attenuation are significant, the most challenging obstacle to imaging a large 
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portion of pancreas will be how to deliver enough laser power through an optical fiber. For 
photoacoustic imaging to visualize biomarkers of PDAC, molecular probes must be 
developed and evaluated for extravasation, binding efficiency, excretion, and toxicity.79 
Early stage preclinical applications in pancreatic cancer animal models support the value of 
photoacoustic imaging for early detection of PDAC,80 pending further development of 
operational and visualization techniques.
EUS-guided Aspiration of Portal Venous Circulating Pancreatic Tumor Cells
The fact that tumor cells intravasate into the vascular system and appear in the peripheral 
blood has been known for over 100 years, but techniques to reliably capture and identify 
circulating tumor cells (CTCs) have been developed only since 2000.81 CTC analysis 
requires cell capture and cell detection systems to concentrate the CTC sample, because 
there is roughly 1 CTC for every 107 circulating blood cells.82 The number of CTCs is low 
in early stage disease and, until recently, has been thought to be too low to contribute to the 
detection and assessment of upper GI tract malignancies including PDAC. In 2004, Allard et 
al83 were able to detect CTCs in 6 of 16 patients with PDAC, and subsequent refinements in 
cell capture technologies have resulted in a growing number of observations including the 
finding that circulating pancreatic epithelial cells can be detected in the presence of 
premalignant cystic disease.84
Pancreatic venous effluent in the portal venous system is an obvious potential source of large 
numbers of CTCs in PDAC, and in 2015, Catenacci et al85 demonstrated that EUS-guided 
transhepatic aspiration of portal venous blood was safe and yielded relatively large numbers 
(~ 100 CTCs per 7.5 mL blood) of PDAC CTCs. Further, these CTCs contained the same 
mutations as seen in regional lymph nodes of patients who later underwent surgery. 
Subsequently, this group reported that the number of portal vein CTCs (PV-CTCs) correlated 
with the metastatic status of the PDAC.86 This predictive or stage-confirming utility of the 
analysis of PV-CTCs has been confirmed by others.87,88 EUS-guided capture of PV-CTCs 
may allow early detection of PDAC, guide treatment strategies, and enable further 
understanding of the biology of PDAC.
Research Gaps and Opportunities
These technical advances in EUS-guided detection and treatment technologies require 
further development and validation. Specific research priorities include: (1) clinical trials of 
contrast-enhanced EUS for the discrimination of benign and malignant disease; (2) further 
development of US contrast agents that are tissue-specific or cell-specific; (3) studies that 
combine digital imaging analysis with standard EUS, contrast-enhanced EUS, and elastogra-
phy in patients with benign and malignant disease; (4) further development of safety studies 
to support U.S. Food and Drug Administration approval of molecular markers of PDAC to 
allow clinical studies of EUS microbubble methods for PDAC diagnosis and cell-directed 
therapy; (5) development of a clinically useful high-intensity focused US endoscope; (6) 
development of a clinically useful endoscopic photoacoustic delivery system; and (7) 
prospective clinical studies to assess the value of PV-CTC capture and analysis for PDAC 
staging and clinical management, and standardization of CTC isolation and enrichment 
platforms with validation studies.
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CONCLUSIONS
This workshop addressed the research gaps and opportunities in the field of pancreatic EUS. 
Diagnostic and therapeutic EUS as applied to both benign and malignant diseases of the 
pancreas has vastly expanded over the last 40 years. Further advances will be possible only 
through the interdisciplinary and multicenter collaboration of endosonographers, clinical 
pancreatologists, biomedical engineers, and laboratory scientists. Priority areas for research 
focus on the following 3 areas: improved methodology of specimen acquisition and 
molecular testing, especially given the rapid growth of personalized medicine; advances in 
sonographic technology and intravenous agents to enable accurate differentiation of benign 
and malignant pancreatic neoplasms by using EUS; and development of novel and 
specialized accessories to make therapeutic EUS procedures safer and more effective. There 
is clearly a need for consortia for clinical trials as well as biospecimen collection and 
processing. These efforts will hopefully translate into better and discriminating use of 
pancreatic EUS.
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Abbreviations
AIP autoimmune pancreatitis
CEA carcinoembryonic antigen
CE-EUS contrast-enhanced EUS
CTC circulating tumor cell
EUS-FNA EUS-guided FNA
IPMN intraductal papillary mucinous neoplasm
LAMS lumen-apposing metal stent
MRI magnetic resonance imaging
PDAC pancreatic ductal adenocarcinoma
PV-CTC portal vein circulating tumor cell
UCA ultrasound contrast agent
WON walled-off necrosis
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